Kornimate/medical-research-clean huggingface dataset:
aspirin resistance and sleep apnea in type-2 diabetic patients

Conditions: Atherothrombosis; Type 2 Diabetes; Obstructive Sleep Apnea Syndrome

Summary: type-2 diabetes and sleep apnea syndrome (sas) are both related to an increase in platelet activation. type 2 diabetes is often associated with sleep apnea syndrome with a prevalence up to 60%. the main objective of our study is to analyze the influence of sleep apnea on the response to antiplatelet therapy in stable aspirin-treated type-2 diabetes patients. consecutive stable aspirin-treated type-2 diabetes patients referred for suspicion of sleep apnea will be recruited after providing informed consent. response to aspirin will be assessed with the verify now aspirin(tm)rapid analyser in the morning after nocturnal polysomnography, and compared with a group of type-2 diabetes free of sleep apnea. other endocrine, metabolic, hematologic and cardiovascular confounders will also be assessed at baseline to determine their influence on the response to aspirin. then, patients with severe sas (apnea-hypopnea index\> 30 events/h) and response with aspirin (aru \> 454) will be randomized to 3 months of active or sham continuous positive airway pressure treatment in a pilot study. after the 3-months of intervention, response to aspirin will be compared between the sham and effective cpap groups.


Eligibility criteria:
inclusion criteria: * men and women aged \> 18 years old * with type 2 diabetes * stable atherothrombosis for more than 3 months * using aspirin for more than 10 days or without aspirin (in this last case, they will do only the observational study.) * without any modification in their treatments for 10 days * ambulatory patient * without any cardiovascular event or inflammatory disease for 3 months before inclusion exclusion criteria: * pregnant women * other active clinically significant illness, including unstable cardiovascular, or neoplasia which could interfere with the study conduct or counterindicate the study treatments or place the patient at risk during the trial or compromise the study participation * patients participating in an other study * patient without any medical care insurance * any treatment that could interfere with aspirin * previous treatment by cpap
a mobile phone based medication reminder program

Conditions: Medication Adherence

Summary: this study evaluates the feasibility and acceptability of using mobile applications to improve medication adherence. participants in the experimental group will receive educational materials and daily reminders through mobile applications. while, participants in the control group will receive only educational materials. after the intervention, interviews will be conducted among participants through phone calls.

the purpose of this study is to improve medication adherence for chinese patients with coronary heart disease (chd) by using mobile applications. an exploratory randomized controlled trial (rct, n=49) and interviews (n=15) will be included in this pilot study. the rct will compare the effects of the medication adherence (ma, n=24) intervention and control condition (n=25) on the ma score (percent of prescribed antihypertensive drugs taken), and health outcomes (sbp and dbp obtained) of patients. the health outcomes will be assessed at enrollment and every three days after the intervention begins for thirty days. feasibility will be determined by the number of patients enrolled, and retention (percent of patients who complete the study). acceptability (read daily reminders and educational materials via mobile applications) will be evaluated through focus group interviews. all analyses will be performed using sas 9.3 (cary, nc). the potential risks of this study are minimal.

Eligibility criteria:
inclusion criteria for participants are: * having a medical diagnosis of chd * being eighteen years old or older * having an antihypertensive medication regimen that lasts for forty-nine days or more at the enrollment * being able to read messages through mobile phone * having a mobile phone which can receive messages from wechat, and can receive daily reminders from bb reminder * having no obvious cognitive impairment * patients with comorbidities can be included in the study, but during the study, antihypertensive medications are their only prescribed medications (this will be screened by the cardiologist).

Keywords: medication adherence mhealth china heart disease
study of personalized immunotherapy in adults with metastatic colorectal cancer

Conditions: Colorectal Neoplasms

Summary: this study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted listeria monocytogenes (pladd) treatment in adults with metastatic colorectal cancer.

this single arm study is designed to evaluate the safety and tolerability of a personalized treatment in adults with metastatic colorectal cancer by first analyzing the expression of tumor-associated antigens and then treating the patients with a personalized live, attenuated, double-deleted listeria monocytogenes (pladd)-based immunotherapy. pladd is based on the attenuated form of listeria monocytogenes that has been genetically modified to reduce its ability to cause disease, while maintaining its ability to stimulate a potent immune response. pladd is manufactured using patient-specific antigens and is therefore individualized to each patient.

Eligibility criteria:
inclusion criteria: * metastatic colorectal cancer (mcrc) that is microsatellite stable (mss) * able to provide adequate tumor tissue from at least 1 accessible tumor site * completed or have developed intolerance to a course of oxaliplatin- or irinotecan-based frontline therapy at screening * on maintenance standard-of-care chemotherapies or on treatment holiday * eastern cooperative oncology group (ecog) 0 or 1 * adequate organ function * progression of disease at the time of enrollment exclusion criteria: * braf v600e mutation * known allergy to both penicillin and sulfa drugs * implanted devices that cannot be easily removed * immunodeficiency, immune compromised state or receiving immunosuppressive therapy

Keywords: metastatic microsatellite stable (mss)
relationship between electrical pain tolerance threshold of alveolar ridge and individual attributes

Conditions: Intraoral Pain Threshold

Summary: this study was conducted with an aim to know how individual attributes associated to intraoral pain tolerance threshold. the hypotheses were that the pain tolerance threshold associated to age, sex, prosthodontic oral condition evaluated by the eichner index, and psychological state evaluated by the profile of mood states.


Eligibility criteria:
inclusion criteria: * not pacemaker wearers exclusion criteria: * general health problems that could affect the measurement of nerve activity a lack of understanding of written or spoken japanese
the efficacy of yiqifumai injection as an adjunctive treatment for sepsis

Conditions: Sepsis

Summary: this is a prospective single center pilot randomized controlled study to assess the efficacy and safety of yiqifumai injection (yqfm), a widely used chinese medicine, as an adjunctive treatment for sepsis.

sepsis is a major clinical challenge with high mortality and morbidity worldwide. sepsis is characterized by the dysregulated host response to an infection followed by organ dysfunction. early sepsis mortality has diminished with advances in intensive care management and goal-directed interventions, only to surge after "recovery" from acute events, which prompts a search for sepsis-induced alterations in immune function. when suffered from sepsis, patients may have evidence of hyper-inflammation and immunosuppression. there are no high-quality evidence examining the effect of intravenous (iv) immunoglobulins or other immune modulators on the outcomes of patients with sepsis or septic shock. yiqifumai injection (yqfm) is a redeveloped preparation based on the traditional chinese medicine formula sheng-mai-san, which is widely used in clinical practice in china, mainly for the microcirculatory disturbance-related diseases. yqfm is proved to be effective for treating sepsis (unpublished data). and several researches reveal that yqfm attenuates acute respiratory distress syndrome and lipopolysaccharide-induced microvascular disturbance in vitro. the purpose of this study is to explore the adjunctive treatment effect of yqfm to prognosis, immune dysfunction and organ dysfunction of sepsis.

Eligibility criteria:
inclusion criteria: * sepsis defined by sepsis-3 definition * adult patients between the ages of 18 and 90. * informed consent is provided by patients or obtained by family member if patient is incapacitated. exclusion criteria: * known severe allergic reaction to drugs including but not limited to yqfm. * pregnant patients or those who may be pregnant * patients with severe intracranial diseases (intracranial artery stenosis, intracranial infection, cerebral hemorrhage, cerebral infarction, brain trauma, subjects after intracranial surgery) * patients with extremely severe brain injury, after cardiopulmonary resuscitation, advanced malignant tumor, combined with serious primary diseases such as liver, lung, kidney and hematopoietic system, and poor prognosis; * autoimmune diseases, immune deficiency diseases, continuous use of immunosuppressants within the last 6 months, or organ transplants; * major surgery or trauma within the last 2 weeks; * participated in other clinical trials or took similar drugs within 1 month; * the investigator considered that the subjects had poor compliance or other clinical, social, or family factors that were inappropriate for inclusion in the study.
utility of sortilin as a biomarker of restenosis after lower extremity endovascular revascularization

Conditions: Peripheral Artery Disease

Summary: sortilin is a 95-kda protein related to circulating cholesterol. it is found inside different cell types and circulating in blood and it has been associated with the risk of atherosclerosis development and cardiovascular diseases. the goal of this observational study is to evaluate the potential use of circulating sortilin as a biomarker of vascular adverse outcomes in patients with peripheral artery disease (pad) and chronic limb-threatening ischemia (clti) requiring a procedure of endovascular revascularization. the main questions it aims to answer are: * association between sortilin serum levels and risk of restenosis after lower extremity revascularization. * association between sortilin serum levels and acute limb ischemia, major vascular amputations, and limb-threatening ischemia needing for urgent revascularization after lower extremity revascularization. patients with pad and clti requiring lower extremity endovascular revascularization will undergo blood sampling for the dosage of circulating sortilin before the endovascular procedure. incidence of restenosis and acute limb ischemia, major vascular amputations, and limb-threatening ischemia needing for urgent revascularization will be collected in a 12-months follow-up and will be associated with sortilin serum levels at baseline.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus diagnosis; * ankle/brachial index (abi) of less than 80; * at least one lower limb stenosis greater than 50% documented by ultrasound color doppler (us); * stage 4 or 5 pad diagnosis according to the rutherford classification; * presence of chronic limb threatening ischemia; * indication for ler of the target arterial stenosis. exclusion criteria: * statin therapy within the previous 3 months; * revascularization of the lower limb in the previous 3 months; * diabetic foot ulcers with signs of active infection or osteomyelitis; * diabetic peripheral neuropathy; * homozygous familial hypercholesterolemia; * absolute contraindication to antiplatelet therapy; * thrombophilia; * active cancer; * active autoimmune disease; * liver disease at functional status b or c according to child-pugh.

Keywords: sortilin peripheral artery disease restenosis acute limb ischemia amputation limb-threatening ischemia
efficacy and safety of thrombopoietin in patients with severe and very severe aplastic anemia

Conditions: Anemia, Aplastic

Summary: efficacy and safety of recombinant human thrombopoietin in patients with severe aplastic anemia and very severe aplastic anemia, a randomized, double-blind, placebo-controlled, ii phase, multi-center clinical research.

rhtpo

Eligibility criteria:
inclusion criteria: * able to provide written informed consent * have severe or very severe aplastic anemia exclusion criteria: * have diagnosis of fanconi anemia * have infection not adequately responding to appropriate therapy * have paroxysmal nocturnal hemoglobinuria (pnh) clone size in neutrophils of greater than or equal to 50% * have creatinine and/or blood urea nitrogen (bun) ≥2 times the upper limit of normal * have serum bilirubin ≥ 1.5 times the upper limit of normal, or ≥4.0 times the upper limit of normal if the patient has been treated with anti-thymocytes globulin（atg） within three weeks of screening. * have glutamic-oxaloacetic transaminase （ast） and/or glutamic-pyruvic transaminase （alt） ≥ 3 times the upper limit of normal * are female and are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential * have an eastern cooperative oncology group (ecog) performance status of 3 or greater * have had other thrombopoietin (tpo-r) agonists medication in the previous 4 weeks.
a comparison of paliperidone and risperidone for treatment of patirnts with methamphetamine-associated psychosis

Conditions: Methamphetamine Dependence

Summary: methamphetamine-associated psychosis (map) has been considered a pharmacological or environmental pathogen model of schizophrenia (scz) due in part to similarities in clinical presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms), response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic neurotransmission) of both conditions. both paliperidone and risperidone are second generation antipsychotics，but have same pharmacological effects of antipsychotic treatment and paliperidone may have more efficacy and safty.this study was designed to examine the acute efficacy, safety, and tolerability of paliperidone and risperidone for patients with map.

methods:a multiple-center, randomized, double-blind.

Eligibility criteria:
inclusion criteria: 1. patients,diagnostic and statistical manual of mental disorders 4thed. (dsm-iv) criteria for methamphetamine-associated psychosis. 2. must sign a information consent form. 3. required to provide detailed address and phone number exclusion criteria: 1. serious organic disease. 2. suicide ideation or hurt others. 3. taking antipsychotic within two weeks before. 4. drug allergy to risperidone or paliperidone. 5. pregnancy and breastfeeding women.

Keywords: methamphetamine-associated psychosis aripiprazole risperidone
shortness of breath in the emergency department (shortie)

Conditions: Acute Myocardial Infarction; Heart Failure; Pulmonary Embolism

Summary: shortie is a two-phase study to determine the impact of the triage profiler s.o.b. (shortness of breath) panel on patient management, outcome, and cost.

patients presenting to the ed with a primary complaint of shortness of breath will a have blood sample collected at enrollment and tested using the triage® profiler s.o.b. panel (measuring creatine kinase mb \[ck-mb\], myoglobin, troponin i, b-type natriuretic peptide \[bnp\], d-dimer). the test is used as an aid in the diagnosis of myocardial infarction (mi), an aid in the diagnosis and assessment of severity of heart failure (hf), and an aid in the assessment and evaluation of disseminated intravascular coagulation including pulmonary embolism (pe). phase i is an observational study and results of the triage profiler s.o.b. panel will be blinded to all attending physicians and health care workers. in phase ii, patients will be assigned to either the experimental arm or the control arm of the study. in the experimental arm, the triage profiler s.o.b. panel results will be available to the treating physician and can be incorporated into the decision making process. in the control arm, treating physicians and staff will be blinded to the triage profiler s.o.b. panel results. time to appropriate treatment, length of ed stay, patient outcome and hospital costs will be assessed in all patients and used to determine the impact of triage profiler s.o.b panel on these parameters. furthermore, the diagnostic accuracy of the triage profiler s.o.b panel will be calculated.

Eligibility criteria:
inclusion criteria: * age 18 and older. * visit to the ed is due to a primary complaint of shortness of breath alone or shortness of breath with associated chest pain, cough or edema. exclusion criteria: * blood sample cannot be collected before treatment is initiated, specifically cpr or treatment with i.v. diuretics, injectable anticoagulants, thrombolytics * patient is unwilling or unable to give consent to participate in the study * patient has renal disease requiring dialysis * patients with a clear exacerbation of isolated asthma * patients with trauma that interferes with normal breathing function
a phase 1 study of ocv-c02 in patients with advanced or relapsed colorectal cancer

Conditions: Colorectal Cancer

Summary: to assess the safety and tolerability of ocv-c02 in patients with advanced or relapsed colorectal cancer who are refractory or intolerant to standard chemotherapy

the incidence of dose limiting toxicity (dlt) will be evaluated in cohorts of six patients by starting ocv-c02 administration at dose level 1 (ocv-103 and ocv-104 at 0.3 mg each), increasing the dose to dose level 2 (at 1 mg each), level 3 (at 3 mg each), and then up to dose level 4 (at 6 mg each). once-weekly administration will be repeated four times in each treatment cycle, and the incidence of dlt from day 1 to day 29 will be evaluated. at the end of cycle 1, patients who wish to continue ocv-c02 treatment and have provided their written consent will be permitted to continue participation in the trial using the same dosing schedule for each subsequent cycle as that for cycle 1.

Eligibility criteria:
inclusion criteria: * patients who have human leukocyte antigen (hla)-a\*24:02 * patients who have histologically-confirmed colorectal cancer (adenocarcinoma) * patients with advanced or relapsed colorectal cancer who are refractory or intolerant to standard chemotherapy * patients with an eastern cooperative oncology group (ecog) performance status (ps) of 0 to 1 at the time of enrollment in the trial. exclusion criteria: * patients who are hiv antibody test positive * patients with an active infection * patients who have or are suspected to have cns metastasis of colon cancer (such as metastatis of the brain)

Keywords: ocv-c02 colorectal cancer antigen specific cancer immunotherapeutic
technology assisted physical activity among hospitalised medical patients

Conditions: Pulmonary Disease; Cardiac Disease; Geriatric Disease

Summary: research show that inactivity during hospitalization is the norm and that the negative effects on muscle mass and the fitness of the patient will take a long time and hard work to recover afterwards. especially for weaker elderly patients, just a few days in bed could mean that they are not able to take care of themselves afterwards, with increased care expenses and increased risk of relapse as a consequence. even though this is known, the work to motivate patients to be active during their hospitalization is limited to few training sessions with only the most vulnerable patients. no tools are today available for objectively tracking and motivating patients to be active during their stay. having such a professional tool would not only motivate but also shift the attention of the health professionals towards the importance of physical activity in the treatment of the patient. the aim of the studys is to investigate if patients hospitalised for medical disease will increase their time spent out of bed during hospitalisation through simple visual feedback about physical activities from a mobile bedside device.

the study will be conducted as a quasi-randomised trial using a large tertiary public hospital in copenhagen, denmark. patients admitted to department of respiratory medicine (2 wards), department of cardiology, and department of geriatrics will be included, and they will have their physical activity level measured either with or without a bedside monitor providing visual feedback of time spent bedridden, sitting, standing and walking. all participants will have their physical activity measured during hospitalisation. approximately half of the participants will receive visual feedback about the amount of physical activity from a mobile device placed on the bedside table.

Eligibility criteria:
inclusion criteria an individual will be eligible for study participation if he/she meets the following criteria: 1. is admitted to one of the participating departments 2. has signed informed consent 3. reads and speaks danish exclusion criteria an individual will be excluded from the study if he/she meets any of the following criteria: 1. any condition that, in the opinion of the investigator, makes the person unfit for participation 2. expected hospitalisation less than 24 hours 3. has no independent ambulatory abilities (e.g. wheel chair user) 4. needs personal assistance in body transfers and ambulation (cumulated ambulation score 0, 1, 2, or 3) 5. has allergy towards band aid
implementation and effectiveness of a psychosocial intervention among registered people living with hiv(hiv patients) at pakistan institute of medical sciences (pims) islamabad pakistan.

Conditions: HIV Positive

Summary: "implementation and effectiveness of a psychosocial intervention among registered plhiv at pims islamabad pakistan." the study aims to evaluate the impact of a structured psychosocial intervention on the mental health and well-being of people living with hiv (plhiv) registered at pims. study highlights: 1. participants: registered plhiv receiving care at pims. 2. data tools: standardized measures (e.g., dass-21, who-5 well-being index). 3. design: randomized control trial (rct) with intervention and control groups, including pre- and post-intervention assessments. 4. ethical approval: approved by pakistan institute of medical sciences pakistan islamabad's ethical review board

"implementation and effectiveness of a psychosocial intervention among registered plhiv at pims islamabad pakistan" the study aims to evaluate the impact of a structured psychosocial intervention on the mental health and well-being of people living with hiv (plhiv) registered at pims. study highlights: 1. participants: registered plhiv receiving care at pims. 2. data tools: standardized measures (e.g., dass-21, who-5 well-being index). 3. design: randomized control trial (rct) with intervention and control groups, including pre- and post-intervention assessments. 4. ethical approval: approved by pakistan institute of medical sciences pakistan islamabad's ethical review board

Eligibility criteria:
inclusion criteria:• 1:plhiv who are registered at hiv treatment centre at pims islamabad. * 2:plhiv who are registered and visiting for regular follow up * 3:participants willing to provide written informed consent.(acceptance or willing of participants) exclusion criteria: * 1:plhiv who are registered, but with other co morbidities like tb, hepatitis bc, cardiac issues etc. * 2:plhiv who are registered and admitted due to severe any co morbidities. * 3:plhiv who are registered and are already involved in other studies * 4:plhiv who are registered and have history of receiving any psychosocial support or counseling before this study. * 5:participants not willing to provide written informed consent.(refusal of participants).